Seguimiento farmacoterapéutico en pacientes con terapia de inhibidores de la bomba de protones, del servicio de medicina interna del Hospital Provincial General Docente Riobamba

Abstract

The aim of this work was the pharmacotherapy follow-up of patients who received proton pump inhibitors as pharmacotherapy in the internal medicine area of the Hospital Provincial General Docente of Riobamba during July-September 2021. A descriptive, prospective and cross-sectional analysis of patients admitted to the aforementioned department was carried out and a total of 437 medical records were reviewed, of which, according to the inclusion and exclusion criteria, only 37 cases were studied. As a result of this investigation, it was obtained that the main treatment administered to patients was gastroprotective therapy 54.04%, identifying an irrational use of omeprazole and high unnecessary hospitalization costs. In addition, 68.54% of drug interactions and 12.36% of medication errors due to inappropriate use of the drug were determined. With the pharmacological interventions carried out, the unjustified use of omeprazole was reduced and health education assistance was provided, in the same way, the Dader method was used as a guide to detect, prevent and solve medication problems by means of interviews and survey tools, obtaining that 84% of the health problems detected were resolved through patient education. It was concluded that there was a high risk of Drug-Related Problems (DRPs) in the studied patients, however, the appearance of negative outcomes associated with the medication could not be confirmed since, during the administration of pump inhibitors protons, no changes were observed in the health of the patients. It is recommended to extend the study to a pharmacoeconomic analysis in order to verify the expense produced by the irrational use of proton pump inhibitors and also carry out research with clinical practice guidelines.